On Sept 10, Li Li, commissioner of the National Medical Products Administration (NMPA), met in Beijing with a delegation led by Raymond Chua Swee Boon, chief executive officer of the Health Sciences Authority (HSA) of Singapore.

The two sides engaged in-depth discussions on further strengthening cooperation in drug and medical device regulation between China and Singapore.

Li introduced China's drug regulation efforts and the development of the pharmaceutical industry. He said that in recent years, the NMPA has continuously prioritized ensuring drug quality and safety as its most fundamental responsibility. The NMPA has also deepened the reform of the drug review and approval system, and enhanced drug regulatory capacity, so as to comprehensively promote the scientific, rule-based, international, and modern development of drug regulation.

Chua presented the HSA's responsibilities and drug regulation work, as well as its participation in international drug regulatory harmonization and the establishment of reliance and cooperation mechanisms in drug and medical device review with other countries.

The two sides exchanged views on promoting mutual reliance in drug and medical device regulation between China and Singapore, as well as the regulation of traditional Chinese medicines.

They agreed to deepen practical cooperation in drug regulation and jointly improve the quality and efficiency of drug regulation to further enhance the health and well-being of the people of both countries.

Officials from relevant departments and affiliated institutions of the NMPA were also present.